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Background: Intermittent Claudication (IC) is pain on walking that is related to poor 
blood supply to the lower limbs. Endothelial dysfunction is thought to play a role in the 
onset and progression of this condition. The idea that short periods of non-lethal 
ischaemia followed by periods of reperfusion, in one organ or tissue, triggers 
endogenous protective pathways in other organs is known as Remote Ischaemic 
Preconditioning (RIPC). RIPC has been shown to improve endothelial function by 
increasing bioavailability of NO. The study aims to evaluate whether RIPC can improve 
markers of vascular function by assessing its effect in participants with IC compared 
to healthy volunteers.  
 
Methods: Seventeen participants were recruited and underwent four days of RIPC 
protocol. Vascular function was assessed using (i) iontophoresis with Laser Doppler 
Imaging (LDI), (ii) Post occlusive reactive hyperaemia test (PORH) (iii) pulse wave 
analysis (PWA) and pulse wave velocity (PWV) to measure arterial stiffness. Blood 
samples were also taken to assess for any change in serum cytokines and markers of 
oxidative stress.  
 
Results: Multiple regression analysis demonstrated a statistically significant 
improvement in PWA, after RIPC intervention, in healthy volunteers only (p ≤ 0.05 is 
used as statistical significance). There were no other significant predictors of change 
in vascular function after RIPC. 
 
Conclusion: RIPC appears to show improvement in arterial stiffness as measured by 
PWA. The results suggest that RIPC has a greater beneficial effect in healthy 
volunteers as opposed to patients with IC. The results do not support the idea that 
improvements in vascular function are solely mediated through improvement in 
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AIx Augmentation Index 
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cGMP Cyclic Guanosine Monophosphate 
CK-MB Creatine Kinase-Myocardial Band 
CRP C-Reactive Protein 
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DVT Deep Vein Thrombosis 
EDHF Endothelium-derived Hyperpolarising 
Factor 
eNOS Endothelial Nitric Oxide Synthase 
FMD Flow-Mediated Dilatation 
FLPI Full Field Laser Perfusion Imager 
GTP Guanosine triphosphate 
HDL High Density Lipoproteins  
HV Healthy Volunteer 
IC Intermittent Claudication 





IPC Ischaemic Preconditioning 
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SOP Standard Operating Procedures 
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Transcription 3 









7.1 CARDIOVASCULAR DISEASE 
 
Cardiovascular disease (CVD) is a major health burden worldwide and within the UK. 
In 2014 cancer was the leading cause of mortality in the UK, accounting for 29% of all 
deaths. CVD was responsible for 27% of all deaths in the UK which equates to a total 
of approximately 155,000 deaths in the year(1). Although CVD represents a heavy 
burden of disease the number of deaths as a result of CVD has been declining steadily 
each year(1). A large part of this is as a result of lifestyle modification and improved 
medical management. Peripheral arterial disease (PAD) is a term used to describe a 
condition whereby blood flow to the extremities is compromised or reduced. Most 
commonly it is the legs that are affected. Blood flow is disrupted by narrowings, called 
stenoses, or occlusions within an artery. In the majority of the population it is 
atherosclerotic disease which is responsible for this. One of the most common clinical 
manifestations of atherosclerotic disease in the lower extremities is pain on walking, 
or Intermittent Claudication (IC), as it is generally referred to in a clinical setting. 
Intermittent claudication is acute onset pain, on exertion, that resolves on resting. 
Patients can experience pain on walking in the calf, thigh, buttocks or a combination 
of these sites. The site where pain is experienced is usually related to the site of 
disease within the arterial network. Arterial occlusions or stenoses tend to be above 
the site of pain i.e pain in the calf muscles is usually as a result of occlusion / stenosis 
of the common femoral, superficial femoral or popliteal arteries. Pain in the thigh or 
buttocks is usually related to disease in the aorta or iliac arteries. The incidence of 
PAD in the UK is about 3-10% in people aged 70 or less and approximately 15-20% 
in those over 70 years of age(2). Most patients are asymptomatic, while 1 in 10, 
present with symptomatic disease in the form of IC. In symptomatic patients 3-5% will 
end up requiring a major amputation(3). A healthy functioning endothelium plays an 
important role in vascular tissue homeostasis and endothelial dysfunction is 











The endothelium is a thin monocellular layer that covers the inner surface of the body’s 
arteries. The endothelium, one of the largest organs in the body, is extremely active. 
It is a paracrine, exocrine and endocrine organ and releases factors that control 
vascular relaxation and contraction, thrombogenesis and fibrinolysis, and platelet 
activation and inhibition. The endothelial cell is similar to other cells in the body. A 
cortical web surrounds the internal surface of the sarcolemma (Figure 1). This cortical 
web is affected by changes in intravascular tension and responds to increases in 
intravascular pressure by increasing its stiffness(5). The integrity of the cortical web is 
important in regulating the adhesiveness of leukocytes and platelets which is important 





Figure 1: General structure of vascular endothelial cell. Adapted from Esper et. al(5) 
 
The major risk factors for CVD, such as hypertension, diabetes, dyslipidaemia and 
tobacco toxins, are also risk factors for endothelial dysfunction. Diseased endothelial 
vessel walls become stiffer and their capability for vasodilatation is reduced(6), which 
hampers the regulatory role that the endothelium provides. Various studies have 
demonstrated that there is an increased risk of cardiac events in patients with severe 
coronary endothelial dysfunction despite only mild coronary artery disease and that 
endothelial dysfunction was also predictive of increased risks of cardiac events 
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independent of the classic risk factors for coronary artery disease(7)(8). Decreased 
availability or activity of nitric oxide (NO) can be an early sign of atherosclerosis. Nitric 
Oxide is a major vasodilator released by the endothelium and is synthesized in 
endothelial cells from L-arginine by the calcium calmodulin-dependent enzyme nitric 
oxide synthase (NOS) (9). In a competent blood vessel most nitric oxide is presumed 
to arise from the activity of endothelial Nitric Oxide Synthase (eNOS) (10) and it is 
thought that shear stress increases the expression of eNOS. Shear stress is an 
important haemodynamic factor initiating and driving the inflammatory process. It is 
felt that low shear stress (<4 dyne/cm2), which is prevalent at sites prone to 
atherosclerosis, such as arterial bifurcations, can stimulate atherosclerosis(11) 
whereas at >15dyne/cm2, observed in healthy arteries, an atheroprotective effect is 
conferred.  NO can also pass through the endothelial intima and penetrate the smooth 
muscular tissue of the arterial wall. NO then, through nitrosilation of the haem from 
guanylate-cyclase, degrades the guanosine triphosphate (GTP) releasing cGMP. This 
consequently regulates the cytosolic calcium and causes smooth muscle fibre 
relaxation and therefore vasodilatation(12).  
 
Nitric oxide performs numerous functions important in maintaining a healthy 
endothelium. It mediates endothelial dependent vasodilation. It achieves this by 
opposing angiotensin II and endothelin I. Angiotensin II is formed by hydrolysis of 
angiotensin 1 via the angiotensin converting enzyme. It initiates its prothrombotic and 
vasoconstrictive effects via the angiotensin II receptor type 1. Angiotensin II stimulates 
endothelin converting enzyme which degrades big-endothelin releasing Endothelin-I, 
which is a powerful vasoconstrictor. NO reduces platelet adherence and aggregation, 
leukocyte adhesion and infiltration, and, prevents oxidative modification of low-density 
lipoprotein (LDL) cholesterol(13). Caveolae are flask shaped invaginations in the 
lumen border of endothelial cells. The plasma membrane of caveolae contain the 
cholesterol rich Caveolin-1 protein. Caveolin-1 has a specialised scaffolding domain 
which organises certain interactions between Caveolin-1 and signalling molecules 
such as eNOS. Caveolin-1 production is increased by oxidised LDL which inactivates 
eNOS thus inhibiting production of NO(14). It has been suggested the caveolae may 
compartmentalise signalling in the plasma membrane and that the interactions 
between resident proteins, such as eNOS, and Caveolin-1 may alter a signalling 
cascade(15).  
 




Reactive oxygen species (ROS) are thought to be predictive of CVD(16). ROS are 
produced in the mitochondria by oxidative phosphorylation or by the actions of 
nicotinamide-adenine dinucleotide phosphate oxidase (NOX) on oxygen free radicals.  
ROS, such as superoxide (O2¯) and hydrogen peroxide (H2O2), are produced in many 
cell types including endothelial cells and vascular smooth muscle cells. The 
antioxidant enzyme Superoxide dismutase rapidly dismutases O2¯ to H2O2 which in 
turn is eliminated by gluthathione peroxidase and catalase to water. Oxidative stress 
is an imbalance in production of anti-oxidant defences, such as superoxide dismutase, 
and reactive oxygen species(17). Oxidative stress leads to production of 
proatherogenic cytokines such as TNF-a, adhesion molecules and chemokines, 
interleukins IL-1 and IL-6 which inhibit eNOS and subsequently production of NO. The 
pro-inflammatory response drives inflammation which in turn initiates release of more 
pro-inflammatory cytokines and a vicious cycle is created(5).  
 
7.2 PERIPHERAL ARTERIAL DISEASE 
 
As discussed, the symptoms of claudication can be the clinical manifestation of 
atherosclerotic disease in the lower extremities. When we walk there is an increased 
oxygen demand to the muscles of the legs. This demand is accommodated for, in part, 
by vasodilation resulting in augmented blood flow to the muscle groups that require it. 
Patients with IC have been found to have an impaired ability to react to this increased 
demand suggesting that there is impaired vasodilation within the vessel. The more 
severe the disease the more severe the impairment in vasodilation(18). In a trial 
comparing healthy volunteers with patients with PAD, vasodilation was induced 
chemically and the resultant vasodilation measured. The superficial femoral artery 
(SFA) is a common site for atherosclerotic disease which can cause IC. In healthy 
volunteers the SFA dilated in response to methacholine and nitroprusside but in PAD 
participants the response was significantly decreased compared to healthy 
controls(19). There is further evidence that this is related to endothelial dysfunction in 
a study that measured endothelial dependent flow mediated dilatation (FMD) in 
participants aged 55 and over and it was found that in the participants with PAD, 60% 
had an impaired dilatory response compared with 32% in an aged matched control 
group(20). The same study also found that raised blood glucose, increased ratio of 
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Low Density Lipoproteins (LDL) to High Density Lipoproteins (HDL) and systolic blood 
pressure were independent predictors of reduced FMD in PAD subjects. Increased 
production of ROS and increased levels of oxidative stress have been demonstrated 
in PAD patients(17)(21) leading to a decrease in the bioavailability of NO. Using 
antioxidant supplementation to improve endothelial function has shown promise in 
some studies. Anderson et. al demonstrated improvement in endothelial dependent 
vasomotor response by administering Lovastatin (lowers LDL) and Probucol 
(antioxidant)(22). Using L-arginine infusions has been shown to improve walking 
distance in participants with diagnosed claudication compared to controls and those 
given an endothelium-independent vasodilator, Prostaglandin E1(23).   
 
7.3 REMOTE ISCHAEMIC PRECONDITIONING 
 
The idea that short periods of non-lethal ischaemia followed by periods of reperfusion, 
in one organ or tissue, triggers endogenous protective pathways in other organs is 
known as Remote Ischaemic Preconditioning (RIPC). In 1986 Murray et al. (24) 
demonstrated, in animal models, that inducing brief periods of ischaemia followed by 
reperfusion in cardiac arteries significantly reduced myocardial infarct size after 
sustained periods of ischaemia, in what was later termed Ischaemic Preconditioning 
(IPC). The researchers achieved this by occluding the left circumflex artery, in the 
hearts of dogs, for 5 minutes and then allowing five minutes of reperfusion. This was 
repeated 4 times after which the same artery was occluded for a sustained period of 
40 minutes causing myocardial infarct. The infarct size in the animals who had been 
‘preconditioned’ was found to be 75% smaller than the control group who had not been 
preconditioned. As interest in this phenomenon grew it was demonstrated by 
Przyklenk et al. (25) that occlusion/reperfusion of one cardiac artery, the left 
circumflex, followed by prolonged occlusion of the left anterior descending artery 
resulted in reduced infarct size. This phenomenon of conferred cardio-protection to a 
remote site not supplied by the artery submitted to preconditioning was termed 
Remote Ischaemic Preconditioning (RIPC). Conditioning that occurs before the period 
of sustained ischaemia is termed Pre-conditioning but research has also focused on 
initiating preconditioning during the ischaemic event (Per-conditioning) and after the 
ischaemic event (Post-conditioning). 
 
 
   
 
18 
The effects of RIPC are not just intracardiac. In a swine model blood flow in the 
hindlegs of pigs was occluded using a tourniquet, in a similar RIPC model, of four 
cycles of five minutes of occlusion followed by five minutes of reperfusion. After the 
RIPC was completed the left anterior descending artery in the pigs was subjected to 
a sustained period of occlusion lasting forty minutes. The infarct size in the pigs 
subjected to RIPC was significantly less that in the control groups not subjected to 
RIPC (26). RIPC can be induced by inflating a blood pressure cuff around one of the 
limbs to a pressure high enough to occlude the targeted artery, pharmacologically (e.g 
diazoxide) or by peripheral nerve stimulation. Due to its non-invasive nature inflating 
a blood pressure cuff to a pressure great enough to occlude the target artery is the 
most straightforward way of inducing RIPC. The exact mechanism of action of RIPC 
is not fully understood but is thought to be a combination of neural and humoral factors. 
Where rabbits who have undergone ischaemic preconditioning had their coronary 
effluent removed and transfused into naïve acceptor hearts. The recipients of the 
transfusion showed significantly smaller infarct size than control groups (27). Like-wise 
in animals where a ganglion blocker such as hexamethonium has been administered 
the cardioprotective effects of RIPC were abrogated in animals who had RIPC induced 
via transient occlusions of the mesenteric arteries, namely the superior mesenteric 
artery (28). The RIPC stimulus initiates production of Nitric Oxide and a number of 
autocoids such as acetylcholine, adenosine, bradykinin, endothelin and opioids, which 
bind to the appropriate receptors on the plasma membrane of cardiomyocytes, which 
in turn stimulate a number of signalling pathways that convey a cardioprotective effect 
to the mitochondria. 
 
As discussed, Nitric Oxide (NO) plays an important role in maintaining a healthy 
endothelium but NO is also thought to play an important role in RIPC. In the context 
of RIPC, occlusion of the artery of interest causes shear stress which activates 
endothelial nitric oxide synthase (eNOS) and in this way levels of NO are increased 
(29). During ischaemia-reperfusion increased levels of NO have been shown to 
attenuate oxidative stress and cell apoptosis (30) 
 
Adenosine is thought to play a significant protective signal transduction role in 
preconditioning. Infusing Adenosine or an Adenosine A1 Receptor agonist was found 
to reduce infarct size in the hearts of rabbits who were subjected to prolonged 
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ischaemia similar to that of those who were preconditioned by five minutes of occlusion 
of a coronary artery followed by ten minutes of recovery (31). Furthermore, they found 
that an Adenosine receptor antagonist reversed the effects of preconditioning but had 
no effect on infarct size on a non-preconditioned heart. A1 receptors are Gi-coupled 
and act to slow the heart rate. Many of these Gi-coupled receptors in the heart can 
mimic Ischaemic Preconditioning (IPC) and in-fact transient occlusion of coronary 
arteries has been found to release ligands for adenosine, bradykinin, opioid and 
sphingosine. It has also been shown that Protein Kinase C (32) and ATP-sensitive 
potassium channels (KATP) (33) were also involved in the ischaemic preconditioning 
pathway. Protein Kinase C (PKC) is a key mediator of many pathological and 
physiological pathways. PKC is made up of 11 phospholipid-dependent serine-
threonine kinases classified by their requirement for calcium and diacylglycerol for 
activation(34). PKC activation is via its translocation to cellular endo-membranes in 
response to second messengers such as calcium or diacylglycerol, although, some 
PKC isoforms are activated independent of calcium. PKC has many isoforms which 
display both beneficial and detrimental effects on endothelial health. Conventional 
PKC (such as PKC ⍺ & ß1/2) translocate on the plasma membrane (Figure 2) and 
produce a vasoconstrictive effect whereas active PKC-ϵ translocates  to the 
mitochondria and has been shown to have a protective effect on cardiac myocytes(35) 
 
	
Figure 2: Signalling pathway for PKC⍺	at the plasma membrane. Adapted from Igumenova 2015(34) 
  
 




7.3.1 RIPC Pathways 
 
Research has tried to focus on finding a universal signalling pathway to explain the 
protective effects that Ischaemic Conditioning creates. The Reperfusion Injury 
Salvage Kinase or Risk Pathway is one proposed by Hausenloy and Yellon (36). 
Myocardial reperfusion injury is the cell death that occurs in the myocardium after 
prolonged ischaemia followed by reperfusion. The RISK pathway attempts to describe 
how a group of survival protein kinases confer powerful cardioprotective effects at the 
time of myocardial reperfusion (37). The pathway was created to provide a blueprint 
for the development of targeted therapies to particular sections of the pathway and it 
has been found that Ischaemic Preconditioning recruits the RISK pathway (38) The 
RISK pathway has several novel features in that it can be activated by Remote 
Ischaemic Preconditioning or Postconditioning and that it includes other 
cardioprotective kinases such as Protein Kinase C, Protein Kinase G, p70s6K and 
GSK-3b (36). It is thought that during the reperfusion stage of RIPC autocoids such 
as adenosine activate P13K & ERK1/2 which in turn activate eNOS. eNOS catalyses 
production of NO which stimulates guanylyl cyclase. This inhibits prolonged opening 
of the mitochondrial permeability transition pores(39).  
 
Another potential pathway that has been shown to be activated by Ischaemic 
Conditioning is the Survivor Activating Factor Enhancement (SAFE) pathway. One 
study demonstrated that TNF-a that was given at the start of myocardial reperfusion 
recruited an alternative signalling cascade termed the SAFE pathway (40). TNF-a has 
a deleterious effect on the myocardium during reperfusion after an ischaemic event. It 
is thought that the cardioprotective effects demonstrated are as a result of uptake of 
TNF-a binding to the TNF receptor 2. This activates the Janus Kinase which recruits 
signal transducer and activator of transcription 3 (STAT-3) which acts on the 
mitochondria by modulating mitochondrial respiration and inhibiting mitochondrial 
permeability transition pores. It has been shown that ischaemic conditioning does 
activate the SAFE pathway (41). The two pathways have been shown to communicate 
with each other as they are both thought to be activated by sphingosine-1-phosphate 
(S1P) (42). Both pathways converge in the mitochondria where they are thought to 
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inhibit the formation of permeability transition pores in the mitochondrial membranes, 
the net effect of this being reduced cell apoptosis during the first minutes of reperfusion 
following an ischaemic event (43). 
 
7.3.2 RIPC and Endothelial Function 
 
Translating results from animal model studies has proved difficult, with some studies, 
including meta-analyses, reporting a beneficial effect of trials of RIPC but also other 
large randomised controlled trials (RCT) which report no significant effect of RIPC. 
One of the first RCTs to report positive results was conducted by Cheung et al., who 
performed four five-minute occlusion / reperfusion cycles using an inflated blood 
pressure cuff around the lower limbs of children prior to them undergoing surgical 
repair of congenital heart defects. Compared to controls the RIPC group had 
significantly lower levels of post-operative Troponin I, indicating less myocardial injury 
post-operatively. The RIPC group also required significantly less inotropic support in 
the post-operative period(44). The Remote IMPACT RCT was an international, 
blinded, parallel-group RCT that measured the serum creatine kinase-myocardial 
band (CK-MB) after patients had undergone major cardiac surgery consisting of 
valvular repair, coronary artery bypass grafting (CABG) or a combination of both. 
There was no significant difference in post-operative CK-MB levels between the RIPC 
and sham RIPC group(45). Looking into the baseline and operative characteristics of 
the patients the RIPC group had more comorbidities with greater numbers having had 
previous cardiac surgery (29 vs 21) and myocardial infarctions (41 vs 35). There were 
more combined CABG and valve repair operations in the RIPC group (45 vs 38). This 
would lead to longer operating times and likely affect post-op CK-MB. In another RCT 
looking at RIPC and its effect on post-operative acute kidney injury (AKI) after cardiac 
surgery the authors(46) reported a significant reduction in AKI (37.5% vs 52.5%, 95% 
CI, 2.56% to 27.44%; P=0.02). They also reported that fewer patients required renal 
replacement therapy post-operatively (5.8% vs 15.8%, 95% CI 2,25% to 17.75%; 
P=0.01). There is mixed reporting for the benefit of RIPC in the post-operative setting. 
One of the noted differences between trials reporting significant results and those not, 
is the type of anaesthetic agent used. It has been suggested that Propofol based 
anaesthetic regimes could explain the lack of significant results observed. Propofol 
has been shown to abrogate the effects of RIPC in rats who have had a Propofol 
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anaesthesia as opposed to those who have had pentobarbitol or sevoflurane(47). It 
may be that preconditioning participants immediately prior to surgery is not an effective 
way to measure the effects of RIPC accurately if the participant is to have a Propofol 
based anaesthetic.  
 
Whilst a lot of research has examined the effects of RIPC in the setting of 
cardiothoracic surgery there is growing evidence that RIPC can improve endothelial 
dysfunction. RIPC can increase circulating levels of eNOS which is responsible for 
most of the vascular nitric oxide produced(48).  RIPC can reduce endothelial 
dysfunction as measured by FMD. Participants were given RIPC immediately before 
an ischaemic insult or at 4hrs, 24hrs and 48hrs before ischaemic insult. When RIPC 
is given immediately before an ischaemic insult it preserves endothelial function (FMD 
9.4 +/- 0.7% vs 8.0 +/- 0.8%). Similarly when RIPC is delivered 24hrs and 48hrs before 
ischaemic insult endothelial function is preserved but not when the insult is delivered 
4hrs after RIPC. This would suggest that there is an early and late phase of protection 
against endothelial injury(49). Most research has employed single bouts of RIPC 
whereas few have examined the effects of repeated daily cycles of RIPC. However, a 
trial in healthy volunteers who took part in a seven day trial of RIPC has previously 
been conducted. Participants had four five-minute occlusion / reperfusion cycles on 
the upper limb for seven consecutive days. The results showed that FMD increased 
after seven days of RIPC (5.0% +/- 2.2% and 6.1% +/- 2.2%, P=0.03). Interestingly 
when FMD was measured in the contralateral arm, FMD had increased suggesting 
that the protective effects of RIPC are conferred to distant organs and tissues(50).  
 
Inducing RIPC by cycles of carotid artery occlusion and reperfusion in mice models 
has shown a significant decrease in cerebral infarct size after sustained occlusion of 
the middle cerebral artery(51). Furthermore the study also demonstrated increased 
immunoreactivity of nitric oxide synthase (NOS) in the cerebral vasculature. The 
effects of RIPC are neutralised in endothelial nitric oxide synthase (eNOS) and 
neuronal nitric oxide synthase (nNOS) null mice(52). RIPC can affect cytokine and 
chemokine expression in inflammatory pathways. It has been shown to decrease pro-
inflammatory cytokines interleukin-1 (IL-1) and interleukin-6 (IL-6) expression and 
upregulates expression of anti-inflammatory cytokines such as IL-10(53). Reproducing 
these results in clinical trials has produced conflicting results. In paediatric cardiac 
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surgery patients who were subjected to RIPC, there was no difference in levels of IL-
6, IL-8, IL-10 or TNF-alpha compared to controls(44) however another similar study 
looked at cytokine levels in patients undergoing orthopaedic procedures. The 
difference in levels of IL-6, IL-8 and Malondialdehyde (a biomarker of oxidative stress) 
were significantly reduced in the RIPC group compared to controls. Zagidullin et al. 
(54) demonstrated an improvement in arterial stiffness and endothelial function, in 
patients with angina, after repeated bouts of RIPC. There is a lack of research 
examining the effects of RIPC on endothelial function in participants with IC. At the 
time of writing no major trials had been completed specifically looking at the effects of 
RIPC in claudicants.  
 
7.4 ASSESSMENT OF MICROVASCULAR FUNCTION 
 
7.4.1 Laser Doppler Imaging with Iontophoresis 
 
Iontophoresis is a well established method of transdermal delivery of small quantities 
of a drug using small electric currents. A Perspex chamber is placed on the skin, most 
commonly the forearm, and drug of choice is placed inside the chamber. A laser 
imager is then placed over the drug chamber to measure the effect of iontophoresis of 




The guiding principle is that molecules of a drug in solution that are either positively or 
negatively charged will migrate across the skin when subjected to a monopolar 
current(55). A positively charged chamber, the anode, will repel a positively charged 
chemical into the skin, likewise, a negatively charged chamber, the cathode, will repel 
a negatively charged chemical into the skin (Figure 3). A reference electrode is 
connected to an iontophoresis controller, and, to the participant being assessed to 
complete the circuit. The polarity of the reference electrode is altered based on the 
charge of the chemical being iontophoresed i.e a positively charged drug will have a 
negatively charged reference electrode and vice-versa.  The amount of drug that 
passes through the skin will depend on 
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• Current – (The greater the current the more the like charges will repel each 
other) 
• Time – (The longer the current is sustained the greater the amount of drug 
absorbed) 
• Skin Resistance (The greater the resistance the lower the concentration of drug 
that will be absorbed) 
 
 
  Figure 3: Diagrammatic representation of concept of iontophoresis 
 
It is thought that ACh facilitates vasodilation during iontophoresis via endothelial 
dependent production of NO (Figure 4) with a possible supporting role played by 
endothelial-derived hyperpolarizing factor (EDHF)(56). Sodium Nitroprusside 
mediates vasodilation independently of the endothelium. SNP reacts with physiologic 
sulphydryl groups and stimulates production of NO directly(57). 
 
 




   
 Figure 4: Role of ACh and SNP in vasodilation. Adapted from Turner et. al 2008.(56) 
 
 
Laser Doppler Flowmetry & Laser Doppler Imaging 
 
The increased blow flow as a result of chemically induced vasodilation can be 
measured using Laser Doppler Flowmetry (LDF) or Laser Doppler Imaging (LDI). LDF 
was first used in this setting but it was limited in that when scanning a drug chamber 
it could only create a single point measurement on the skin whereas LDI could scan 
the area over the entire distribution of the drug chamber allowing a more detailed 
perfusion map. The LDI apparatus generally consists of a coherent light source which 
is usually a monochromatic laser with a long coherence length, a fast detector and a 
software unit for recording and analysing the detecting signal(58). The LDI detects 
moving red blood cells and static tissue. Moving red blood cells undergo a shift in 
frequency proportional to their velocity according to the Doppler principle(56). The 
difference in moving red blood cells and static tissue allows the LDI to build up a 
measurement of ‘flux’ which is an estimate of the blood flow. This ‘flux’ is expressed 
in arbitrary units called Perfusion Units (PU). 
 
It has been shown that human cutaneous microvasculature can be used as a 
surrogate marker for systemic microvascular function(59). Khan et. al(60) 
demonstrated that assessment of cutaneous blood flow response to iontophoresis of 
ACh and SNP showed a positive, statistically significant, correlation with vasodilatory 
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response to adenosine within the Left Anterior Descending coronary artery suggesting 
that cutaneous blood flow is representative of the coronary circulation. In a study 
comparing young Type I diabetic patients with no clinically evident micro or 
macrovascular complications, with healthy controls, a reduced response to 
iontophoresis of ACh and SNP was found to be statistically significant (p < 0.001, for 
both ACh & SNP)(61). Furthermore reduced vasodilatory response to ACh, which is 
endothelial dependent, was significantly correlated with duration of diabetes and poor 
glycaemic control (p < 0.001). 
 
Iontophoresis and LDI have their advantages in that it is a non-invasive assessment 
method, and it has been shown that changes of the microvasculature are 
representative of the systemic vasculature. It allows drugs to be introduced into the 
circulation without any needling or direct infusion into vessels. The amount of drug that 
needs to be used is very small and as these small quantities are absorbed trans-
dermally it avoids first-pass metabolism. However, there can be complications arising 
from the procedure. Although rare it is recognised that side-effects such as skin 
irritation or burn can occur. This generally resolves over time but needs to be relayed 
to any potential study participants. Results can be affected by room temperature, 
recent ingestion of food or drink (tea, coffee) or recent strenuous exercise. These 
factors need to be controlled for to ensure accurate results especially if participants 
are attending over multiple visits. Variations in skin resistance across different 
anatomical sites of the same individual, and across individuals themselves, can affect 
the concentration of drug that passes to the microcirculation. It is thought that certain 
skin areas or individuals will have different levels of hair follicles and sweat ducts, 
which act as paths of least resistance for iontophoresed drugs(62)  
 
7.5 ASSESSMENT OF MACROVASCULAR FUNCTION 
 
7.5.1 Pulse Wave Analysis 
 
Whilst LDI analyses endothelial function within a local vascular bed pulse wave 
analysis (PWA) is a non-invasive way of measuring global endothelial function(63). 
Arterial stiffness is partly dependent on vasomotor tone which itself is partly dependent 
on a functioning endothelium. With each heartbeat an arterial waveform moves 
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centrally through the arterial tree to the peripheral arteries. This waveform can be 
assessed using a highly sensitive applanation tonometer placed over the radial artery. 
The arterial pulse waveform is reflected back to the central circulation and this may 
alter the measured radial waveform. To account for this the computer software uses 
the Augmentation Index (AIx) which is a function of the relationship between the 
reflected arterial wave and the primary aortic wave(63). The AIx represents central 




Figure 5: Aortic Pulse Wave. Adapted from Townsend et. al (2015)(65) 
 
Central arterial stiffness is lower than in peripheral vessels in younger healthy 
individuals. In patients with worsening endothelial dysfunction or atherosclerotic 
disease central arterial stiffness increases and this alters the reflected wave observed. 
The reflected wave is usually observed during late systole but due to increased arterial 














Figure 6: “Aortic pulse wave analysis. (a) Normal/young pulse waveform. Reflected wave during late 
systole, that is, longer ΔTp and Pi occurs after Ps which does not increase left ventricular effort. (b) 
Altered/old pulse waveform. Reflected wave during early systole produces an augmented systolic 
pressure, which decreases blood flow (not shown), and enhances a wasted ventricular effort (dashed 
area). Ps, systolic pressure; Pi, incident pressure from reflecting pressure wave; Pd, diastolic 
pressure; ΔTp, round trip travel time of the reflecting pressure wave; ED, ejection duration. Aortic 
augmentation index (AIx)=((Ps−Pi)/(Ps−Pd)) × 100”. Adapted from Gurovich et. al (2011)(66) 
 
7.5.2 Pulse Wave Velocity 
 
Pulse wave velocity (PWV) is a gold standard for assessing arterial stiffness and it has 
been associated with cardiovascular mortality with an increase in arterial stiffness 
being associated with worse outcome(67). Pulse wave velocity is calculated by using 
a applanation tonometer to measure pulse waves at two different arterial sites. The 
most accurate way is to measure carotid and femoral pulse waveforms. The pulse 
wave velocity is calculated by dividing the distance travelled by the time delay between 
the pressure upstroke at both sites. In young healthy individuals there is a difference 
in pulse wave velocities when looking at central vessels compared to peripheral 
vessels. In the proximal aorta the PWV has been measured at 4 – 6 m/s whilst in the 
more peripheral arteries it is 8 – 10 m/s(68). It is thought that this is because the 
proximal arteries are more viscoelastic compared to the more resistant peripheral 
arteries. A pulse wave will be propagated much more quickly through a stiffer more 
resistant artery than a viscoelastic one(69). In this way a decrease in PWV velocity is 
thought to be associated with improvement in endothelial function.   
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7.5.3 Post Occlusive Reactive Hyperaemia 
 
Post Occlusive Reactive Hyperaemia (PORH) is best achieved by placing a blood 
pressure cuff around the upper or lower limb and inflating it to a pressure that causes 
occlusion of the intended artery (Figure 7). The cuff remains inflated for set period of 
time after which it is quickly released and the resultant rapid increase in blood flow, or 
‘reactive hyperaemia’, is measured.  
 
 
Figure 7: Illustrative set-up for PORH using FLPI 
 
This response involves various mediators that can alter myogenic tone including 
endothelium-derived hyperpolarising factor (EDHF), sympathetic nervous innervation 
of the microcirculation and the endothelial NO dependent pathway, although the latter 
plays a very small role(59). On release of the cuff the increased blood flow causes 
shear stress which stimulates release of NO, which vasodilates, further increasing 
blood flow. The post occlusive change in blood flow is assessed by measuring 
changes in skin microcirculation. This is most commonly done with either LDI or Full 
Field Laser Perfusion Imager (FLPI). The advantage of FLPI in this setting is that it is 
able to capture real time images approximately four times faster than LDI. The 
disadvantages of FLPI in this setting is that it is susceptible to movement artifact and 
participants must remain very still which can be difficult to achieve when a tight blood 
pressure cuff is inflated around one of their limbs. FLPI will be used to assess PORH 
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in the current study. To perform a PORH test there is a resting period, an occlusive 
period and a reperfusion period. During all three phases blood flow is being monitored. 
At the occlusion phase a biological zero is achieved. Despite the arterial occlusion the 
imager will still detect blood flow and it has been suggested that this could be due to 
Brownian movement within the interstitium(56). The biological zero should be 
considered when calculating results. Some advocate that the biological zero should 
be subtracted, others not. It appears that whichever method is used the end results of 
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Primary Objective:  
 
To investigate the relationship between markers of vascular function (endothelial 
function, post-occlusive reactive hyperaemia & arterial stiffness) and repeated cycles 
of remote ischaemic preconditioning. The study will aim to demonstrate an 
improvement from baseline of microvasculature response to iontophoresis of ACh and 




H0 – Repeated cycles of remote ischaemic preconditioning will have no effect on 
vascular function  
 




9 METHODS AND MATERIALS 
 
9.1 SPONSORSHIP AND ETHICAL APPROVAL 
 
Sponsorship and R&D approval was gained locally from the Tayside Medical Science 
Centre and was granted on 19th December 2017. 
 
Ethical approval was sought from the London – Westminster Research Ethics 
Committee. They confirmed that the study would be eligible for a proportionate review 




Seventeen participants in total were recruited to the study. They consisted of nine 
healthy volunteers and eight participants with a clinical diagnosis of intermittent 
claudication. All participants were recruited to the study between 7th February 2018 to 
9th October 2019. Written informed consent was obtained for each patient prior to 
participation in the study. All subjects had an initial consultation to discuss what was 
involved in participating in the study and to give them time to ask any questions they 
had before signing the consent form. Participants attended the blood flow laboratory 
on two separate occasions with each consultation lasting approximately 90 minutes. 
In between each consultation participants were given a manual sphygmomanometer 
and shown how to complete the Remote Ischaemic Pre-conditioning protocol at home. 
The protocol was completed over 4 consecutive days. Microvascular and 
macrovascular assessments were performed before commencing the protocol and 24 
hours after finishing the RIPC protocol. On each visit participants had 40 mls of venous 
blood taken from the antecubital fossa of either the right or left arm to assess for 
markers of cardiovascular risk and were assessed using Iontophoresis, Pulse Wave 
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Consent  √    
Blood samples for 
cytokine analysis 
 √  √ 
Iontophoresis & 
PWA/PWV 
 √  √ 
Remote Ischaemic 
Preconditioning 
  √  
Table 1: Study matrix showing chronological order of study investigations and interventions for each 
participant 
 
On the first consultation each participant was shown how to use the manual 
sphygmomanometer so that they could perform the remote ischaemic preconditioning 
protocol at home. The temperature of the Lab room was kept at 23 °C and patients 
were given 10 minutes to acclimatise before formal assessment started. Participants 
were asked to not smoke, eat any food or take on any fluids for at least 2 hours before 
attending the Lab. 
 
9.2.1 Inclusion & Exclusion Criteria 




• Age 18 years and over 
• Able to give written informed consent 
 
Exclusion Criteria: 
• Positive medical history of upper limb Deep Vein Thrombosis (DVT), Raynaud’s 
disease or Sickle Cell Disease 
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• Previous medical history of upper limb DVT 
• If patient is taking Glibenclamide or Nicorandil 
• If participant has any upper limb fistula 
• Unable to give written informed consent 
• Previous arterial surgery  
• Any contraindication to acetylcholine 
• Any contraindication to sodium nitroprusside 
• Any contraindication to blood pressure cuff inflation 
 
 
9.3 REMOTE ISCHAEMIC PRECONDITIONING 
 
9.3.1 Inducing Ischaemia 
 
Ischaemic preconditioning was induced by placing the cuff of a standard manual 
sphygmomanometer over the biceps of the participant’s arm. An initial blood pressure 
reading was taken to establish a baseline. The cuff was then inflated to a pressure 
20mmHg greater than baseline and the wrist was assessed to ensure there was no 
palpable radial pulse. The cuff remained inflated at the desired pressure for 5 minutes, 
after which it was deflated, and the arm allowed to re-perfuse for 5 minutes. This 
counted as one cycle. In total four cycles were performed, consecutively, each day for 
four consecutive days. Patients were given a rudimentary diary card (Table 2) telling 
them what pressure to inflate the cuff to, and, also as an aide-memoir to help keep 
track of how many cycles they had performed. Participants were told to use the blood 
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 1st Cycle 












Inflate 5 mins 
Deflate 5 
mins 
Day 1  
 
   
Day 2  
 
   
Day 3  
 
   
Day 4  
 
   
Remember: One cycle means inflating the blood pressure cuff for 5 minutes and then deflating it for 5 
minutes. Do this four times and put an X in the box when you have done one cycle.  
Table 2: Diary Card provided to participants to help with completing the trial protocol. 
 
 
9.4 ASSESSMENT OF MACROVASCULAR FUNCTION 
 
9.4.1 Assessment of Arterial Stiffness  
 
Pulse Wave Analysis / Pulse Wave Velocity 
 
Patients were asked to lie supine on a bed for 10 minutes before performing the 
assessment. Pulse wave analysis and pulse wave velocity were measured using the 
cuff based SphygmoCor Xcel (AtCor Medical) device. To measure pulse wave 
analysis the cuff was placed around the upper arm over the normal anatomical lie of 
the brachial artery. The brachial artery waveforms were calibrated using cuff 
measured brachial systolic and diastolic pressures. The system uses a proprietary 
digital signalling and transfer function to generate central aortic pressure waveforms. 
The central aortic pulse wave is used to determine AIx. The system also normalises 
the AIx to a heart rate of 75 bpm (AIx@75) as AIx is affected by extremes of heart 
rate(70).  
 
To measure pulse wave velocity the cuff was placed around the leg of the participant 
midway between the knee and hip. Three measurements were taken using a non-flex 
measuring tape. Distance was measured from the: 
 
 




1. Sternal notch to the carotid pulse 
2. Sternal notch to the proximal edge of the thigh cuff 
3. Femoral artery at the midpoint of the inguinal ligament to the proximal edge 
of the cuff 
 
A PWV value was formulated by calculating the ratio of the corrected distance between 
the carotid and femoral artery pulse measuring sites to the time delay between the two 
pulse waves. 
 
9.5 ASSESSMENT OF MICROVASCULAR FUNCTION 
 
9.5.1 Laser Doppler Imaging 
 
All participants were assessed using LDI (Moor Instruments Ltd., Axminster, UK) 
iontophoresis of acetylcholine and sodium nitroprusside. Participants were asked to 
lie on a bed in the supine position with arms and legs placed in a comfortable position. 
LDI and iontophoresis of ACh and SNP were carried out on the lower legs of the 
participants and the same leg was assessed in each visit. For patients with 
claudication the symptomatic leg was used for each visit. The response to each drug 
was measured on the skin surface of the anterior compartment of the lower leg. The 
skin was prepared by using surgical tape to remove any loose debris on the skin. A 
chlorhexidine wipe was used to clean the area and then allowed to dry. The 
iontophoresis chamber (Moor Instruments Ltd., Axminster, UK) is a Perspex ring, 
measuring 20mm in diameter. A wire electrode penetrates the Perspex ring and inserts 
into the inner surface. A double-sided adhesive tape matched to the shape of the ring 
is attached to the bottom of the ring with the chamber then fixed to the anterior 
compartment of the lower leg. ACh (Sigma-Aldrich, St. Louis, MO, USA) and SNP 
(Sigma-Aldrich, St. Louis, MO, USA) were dissolved in de-ionised water and made up 
to a concentration of 10 g/L (1%). 2mls of this solution were inserted into the chamber 
using a plastic syringe. For ACh the positive lead of a current source was connected 
to the chamber and a negative lead, to act as a reference electrode, was attached to 
a hydro-gel pad which was then placed on the leg 10cm distal to the drug chamber. 
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For iontophoresis of SNP the leads were swapped around. A 2mW helium-neon laser 
was positioned over the leg and focused on the area to be scanned. The area to be 
scanned was mapped out prior to commencing iontophoresis. The laser was 
positioned and calibrated to be 30cm away from the skin surface. The laser and its 
entire metal frame were locked in place to ensure the same area of skin was scanned 
each time (Figure 8).  
 
 
Figure 8: Illustrative set-up of how to perform iontophoresis on a leg 
 
The LDI scans the selected area of the drug chamber for 60 seconds and will continue 
to re-scan the same area according to the protocol being used. Each scan creates a 
colour coded image representing skin blood perfusion over the targeted area. ACh 
and SNP both cause vasodilatation. ACh causes vasodilatation via endothelial 
dependent production of NO. SNP produces nitric oxide directly via reaction with tissue 
sulphydrl groups. The LDI measures back scattered light from moving erythrocytes. 
As vasodilation causes increased blood flow the frequency of the light returning to the 
laser is increased and this change is measured in Perfusion Units (PU).  
 





Figure 9: Scanned images for iontophoresis 
 
When a current is passed through the chamber, the drugs inside iontophorese through 
the skin and get absorbed into the capillaries. Repeatedly passing a current through 
the chamber at regular intervals allows for the concentration to build up which 
increases vasodilation.  A current of 100µA was passed through the chamber for 60 
seconds followed by 60 seconds of no current. This was performed 6 times in total to 
produce twelve images. There were two baseline scans performed before this, and, at 
the end a further scan was performed to ensure the drugs had reached maximum 
concentration. This produced a total of 15 images (Figure 9). The protocol for 
iontophoresis was the same for ACh as for SNP. 
 
9.5.2 Post Occlusive Reactive Hyperaemia 
 
Patients were asked to lie on a bed and acclimatise to the room for 10 minutes. A 
manual blood pressure cuff was placed around the calf muscle of each participant. 
The same leg was used for each assessment. For participants with claudication the 
symptomatic leg was used for each assessment. Skin microcirculation was measured 
over the anterior compartment of the lower leg, below the level at which the blood 
pressure cuff was placed, using a full field laser perfusion imager (MoorFLPI, Moor 
Instruments Ltd., Axminster, UK). The low-power laser beam and a video frame of 10 
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images per second of blood perfusion of microvasculature of the skin was generated. 
A baseline measurement of skin perfusion was measured for 1 minute at which point 
the blood pressure cuff was inflated to a systolic blood pressure of 200mmHg 
occluding blood flow beyond it. None of the participants involved had an on-the-day 
measured blood pressure of greater than 180mmHg. The cuff remained inflated for a 
total of 5 minutes and then rapidly deflated resulting in a rapid return of blood to the 
lower leg. Post-occlusive blood flow was measured for a further 60 seconds. Peak 
perfusion minus biological zero was measured and used for analysis.  
 
9.6 TISSUE ANALYSIS 
 
Tissue 
In total around 80ml of blood was obtained from each participant over two visits with 
40mls of blood being taken for each visit; 40ml for cytokine analysis and 40ml for 
markers of metabolic and oxidative stress.  
 
Unfortunately due to onset of the coronavirus pandemic, and, altered working 
conditions for university and laboratory staff blood samples were not able to be 
analysed in time to be included in the finished study. The samples will be stored so 
that they may be used in further research and their implications for future research 
detailed in the discussion section. 
 
9.7 STATISTICAL ANALYSIS  
 
Baseline characteristics between the healthy volunteers and intermittent claudicants 
were compared using Mann Whitney tests for continuous variables and Fisher’s exact 
tests for categorical data (due to the small sample size). Baseline iontophoresis, PWA, 
PWV and PORH values were compared between healthy volunteers and intermittent 
claudicants using Mann Whitney Tests.  
 
Final iontophoresis, PWA, PWV and PORH values were also compared between 
healthy volunteers and intermittent claudicants using Mann Whitney Tests. Before and 
after RIPC values were compared using Wilcoxon Signed Rank tests for the group as 
a whole, and, healthy volunteers and intermittent claudicants separately. Scatterplots 
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and Spearman’s correlations were used to identify associations between before RIPC 
treatment and after RIPC treatment PWA, PWV and PORH scores. Multiple regression 
models were created to identify any patient characteristics associated with significant 
differences in the final iontophoresis, PWA, PWV or PORH values.  
 
All statistical analysis was performed using SPSS v26. 
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10 TRIAL OF PROTOCOL 
 
As discussed in the introduction there is no general consensus in the literature as to 
what the optimum protocol for inducing RIPC is. Trials with similar protocols have 
reported conflicting results with statistically significant results found in participants who 
underwent one cycle of RIPC induction, and similar results in participants who 
underwent repeated cycles over many days, some as many as twenty-one 
consecutive days. There appears to more robust evidence that better results will be 
obtained by repeated cycles of RIPC over consecutive days and as such we performed 
limited protocol testing, using LDI iontophoresis, in five healthy volunteers to 
demonstrate proof of concept. Two participants performed 4 days of the RIPC 
protocol. Two participants extended the time frame to 7 days of RIPC and one 
participant performed 1 day of the RIPC protocol. All participants were tested before 
induction of RIPC and 24 hours after their last cycles of RIPC. For analysis purposes 
the median values of Perfusion Units (PU) were used as this was how it would be 
calculated in the formal trial. The baseline measurement was the lowest value of the 
first two scans and the peak scan was the highest value of the last two scans. The 
change in flux, as measured in Perfusion Units (PU), is the difference between the 
final scan and the baseline scan. The results for these and the difference in scores for 
before and after the RIPC intervention are notated (Table 3). 
 
 


























1 1 191 142 -49 102 106 4 
2 4 184 192 8 182 133 49 
3 4 128 180 52 189 191 2 
4 7 147 396 249 134 177 43 
5 7 236 620 384 201 188 -13 
Table 3 Change in Perfusion Units (PU) before and after RIPC for ACh and SNP in trial of protocol.  
PU are arbitrary units that are used as a measure of change in blood flow in response to ACh / SNP 
 
 






This participant was a healthy volunteer with no current or past medical history and 
was not taking any prescription medication. They were taken to our laboratory and all 
the same study protocols were followed as were intended for the main trial. This 
participant was assessed using LDI and iontophoresis of ACh and SNP over the 
anterior compartment of the lower leg. The participant then underwent one day of the 
RIPC protocol. This involved four consecutive cycles of five minutes occlusion / 
reperfusion only. The participant was then reassessed using LDI and iontophoresis 24 
hours later. The response from baseline is shown for both ACh and SNP. As can be 
seen the post intervention change in flux was actually lower than baseline (Figure 10). 
 
  
Figure 10: Trial of Protocol graph showing before and after values in Perfusion Units for ACh & SNP 
for participant 1 who had 1 day of RIPC protocol 
 
 
Participant 2 & 3 
 
These participants were healthy volunteers with no current or past medical histories 
and were not taking any prescription medication. They were taken to our laboratory 
and all the same study protocols were followed as were intended for the main trial. 
These participants were assessed using LDI and iontophoresis of ACh and SNP over 
the anterior compartment of the lower leg. The participants then underwent 4 days of 
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reperfusion for 4 consecutive days. The participants were then reassessed using LDI 
and iontophoresis 24 hours after the last cycle of RIPC was performed. The response 





Figure 11: Trial of Protocol graph showing before and after values in Perfusion Units for ACh & SNP 




Figure 12: Trial of Protocol graph showing before and after values in Perfusion Units for ACh & SNP 
for participant 3 who had 4 day of RIPC protocol 
 
 
For participant 2 the RIPC protocol does not seem to have had much of an effect on 
ACh mediated vasodilation. For analysis purposes the median values of Perfusion 
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baseline measurement was the lowest value of the first two scans and the peak scan 
was the highest value of the last two scans. The change in flux, as measured in 
Perfusion Units (PU), is the difference between the final scan and the baseline scan. 
Baseline PU of 184 compared to 192 was observed. Looking at the overall trend in the 
graph there is a much greater peak in ACh post RIPC PU between scans 9 and 12 
indicating a stronger response than perhaps the final numbers convey. We inspected 
the Perspex chamber at the end of the scanning process and although there was still 
small amount of ACh within the chamber there may not have been enough towards 
the end of scanning to cause further vasodilation beyond the peak seen between 
scans 9 and 12. Through the scanning process the drug chambers in some 
participants did need to be topped up with the drug being used. We found that if the 
drug chamber emptied it could produce a spurious increase in PU recorded. For this 
reason we chose to use the baseline and final scan PU for analysis as it was felt this 
would ensure the most accurate data was used. 
 
Looking at the response to SNP in participant 3 the graph suggests the response to 
iontophoresis of SNP was reduced after four days of RIPC but the change in PU, when 
calculated as described above, were broadly similar. Baseline peak PU was 189 
compared to an after RIPC peak PU of 191. Given that our hypothesis is that RIPC 
will improve endothelial function it was predicted that vasodilatory response to SNP, 
which is endothelium-independent, may not differ between pre-intervention and post-
intervention scans. 
 
Participant 4 & 5 
 
These participants were healthy volunteers with no current or past medical histories 
and were not taking any prescription medication. They were taken to our laboratory 
and all the same study protocols were followed as were intended for the main trial. 
These participants were assessed using LDI and iontophoresis of ACh and SNP over 
the anterior compartment of the lower leg. The participants then underwent 7 days of 
the RIPC protocol. This involved four consecutive cycles of five minutes occlusion / 
reperfusion for 7 consecutive days. The participants were then reassessed using LDI 
and iontophoresis 24 hours after the last cycle of RIPC was performed. The response 
from baseline is shown for both ACh and SNP for participants 4 and 5 (Figure 13 & 
14). 
 





Figure 13 Trial of Protocol graph showing before and after values in Perfusion Units for ACh & SNP for 




Figure 14 Trial of Protocol graph showing before and after values, in Perfusion Units for ACh & SNP 
for participant 5 who had 7 day of RIPC protocol 
 
Participants 4 and 5 displayed a much greater effect of RIPC after seven consecutive 
days and ideally we would have chosen to investigate the effects of a 7 day trial. 
Unfortunately the feedback from participants was that completing 7 days in total was 
very time consuming. Participants stated that they felt taking part in the trial was a 
major inconvenience. Data is presented for two participants but initially there were 5 
participants. Three of the participants got in contact to communicate that they hadn’t 
completed the full 7 days of RIPC. The concern was that, with 60% of the participants 
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main study we would have a high drop out rate, or, alternatively if patients did not drop 
out they may not have completed the full 7 days, and not admit this, which would 
weaken any effect size seen. 
 
With this in mind we elected to use a 4 day RIPC protocol in the hope that we would 
avoid a high drop out rate and maintain compliance with the protocol. Although the 
trial of protocol numbers (N=5) were small it was to demonstrate proof of concept using 
iontophoresis for assessment. A positive response to the 4 day RIPC protocol was 














11.1 BASELINE CHARACTERISTICS 
 
Among the seventeen participants eight had a diagnosis of intermittent claudication 
and nine were healthy volunteers. All the Participants with IC were smokers and none 
of the healthy volunteers smoked. Median age in the IC group was 60.0 years and was 
40.0 years in the healthy volunteers which was a statistically significant difference 
(p=0.027). There were no significant differences in gender, systolic or diastolic blood 
pressure between the two groups (Table 4). 
 
 















Statistical test   P value   
      
Age 
Median (IQR) 
 60.0 (14.5) 
 
40.0 (30.5) Mann-Whitney Test 0.027 
      
Sex Male 7 5 Fisher’s Exact Test 0.294 
Female 1 4 
      
Smoking status Smoker 8 0 Fisher’s Exact Test <0.001 
Non-smoker 0 9 





 129 (11) 124 (20.5) Mann-Whitney Test 0.277 





 81.5 (19.75) 80.0 (13.5) Mann-Whitney Test 0.541 
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11.2 BASELINE VALUES 
 
11.2.1 Iontophoresis of Acetylcholine and Sodium Nitroprusside 
 
Alternate repeated currents of 100µA were passed through the drug chamber as 
previously described. The resultant level of vasodilation, measured by change in flux 
or change in perfusion units, was measured by calculating the difference in peak PU 
from baseline PU. These scores were examined, for differences, between healthy 
volunteers and participants with claudication before any RIPC had been commenced. 
There were no significant differences in scores between groups either in response to 
iontophoresis of either ACh or SNP (Table 5). 
 
Table 5 Effect of intermittent claudication on baseline ACh dependent and independent (SNP) 
endothelial function as measured by laser doppler imaging. Mann-Whitney Tests of iontophoresis 
Perfusion Unit (PU) values with study group split into IC & HV 
 
 
11.2.2 Pulse Wave Analysis / Pulse Wave Velocity 
 
There were no significant differences in baseline scores for pulse wave velocity but 
analysis did highlight significant differences between participants with IC and healthy 
volunteers for baseline pulse wave analysis scores (Table 6). 
 
Claudicants had a higher baseline median PWA of 40.0 compared to 11.0 in healthy 
volunteers (p = 0.015) highlighting a significant difference in arterial stiffness 
compared to HV. 
 
 




Statistical test   P value   




215.5 (244.25) 215.0 (127) Mann-Whitney 
Test 
1.000 
     












Table 6 Effect of intermittent claudication on baseline arterial stiffness as measured by PWA and PWV. 
Mann-Whitney of baseline PWA / PWV values comparing IC (n=8) & HV (n=9) groups. PWV is 




11.2.3 Post Occlusive Reactive Hyperaemia 
 
There were no significant differences between baseline PU values for participants with 
IC or HV (Table 7, N=13, p = 0.181).  
 
Table 7 Effect of intermittent claudication on baseline endothelial function as measured by FLPI. Mann-
Whitney test of baseline values for PORH, measured in PU, with study group split into IC (n=7) & HV 
(n=6). 
 
11.3 RESULTS AFTER RIPC 
 
11.3.1 Iontophoresis of ACh and SNP 
 
Examination of median PU values for before and after RIPC intervention did not reveal 
an obvious change in values in response to either ACh or SNP (Figure 15 & 16). In 
the iontophoresis results, a higher score for ACh would indicate an improvement in 
endothelial function. 




Statistical test   P 
value   
 











     
Baseline Pulse Wave Analysis (AIx) 
Median (IQR) 
40.0 (10.75) 11.0 (35.0) Mann-Whitney 
Test 
0.015 
     




Statistical test   P 
value   
 










     
     
 







Figure 15 Box and Whisker plot of change in ACh PU values after RIPC in whole study group 
(n=17). PU Before Treatment: Median = 215, IQR = 188.5; PU After Treatment: Median = 





Figure 16 Box and Whisker plot of change in SNP PU values after RIPC in whole study group 
(n=17).  PU Before Treatment: Median = 130, IQR = 157; PU After Treatment: Median = 144, 
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To look for any differences based on disease status the study sample was separated 
into IC and HV. Although the intervention appeared to have a more beneficial effect 
on healthy volunteers this did not reach statistical significance (Table 8). In response 
to ACh HV had a median increase of 20.0 units compared with 0.5 (p = 0.815). SNP 
mediated vasodilation was slightly less following RIPC for healthy volunteers 
compared with ACh.  
 
Table 8 Effect of RIPC on ACh dependent and independent (SNP) endothelial function as measured 
by laser doppler imaging. Mann-Whitney Tests comparing ACh & SNP Perfusion Unit values between 
IC (n=8) & HV (n=9) 
 
 
Multiple Regression Analysis 
Linear regression analyses were performed to assess any variables associated with 
change in PU. No variables were significantly associated with change in PU. There 
appears to be a trend towards an association between diastolic blood pressure and 
change in PU, however, this did not reach statistical significance (Table 9, p = 0.078) 
in the ACh analysis but was significant in the SNP analysis (Table 10, p = 0.049). 
Looking at the analysis for change in ACh PU it seems that participants were more 
likely to have a lower change in PU if they had a diagnosis of IC although this was not 
significant (p = 0.944). There seems to be a different response to SNP according to 
gender as being female resulted in a greater change in PU after RIPC, although again 
this did not reach statistical significance (Table 10, p = 0.627). Interestingly diastolic 
blood pressure appears to lead to a greater change in PU, potentially suggesting that 








Statistical test   P 
value   
 
Effect of RIPC on Change in PU for 









     
Effect of RIPC on Change in PU for 
SNP, Median (IQR) 
10.0 (205.75) 4.0 (185.5) Mann-Whitney Test 0.888 
 




Dependent Variable: Change in ACh PU  
 
Unstandardized Coefficients 
T statistic P Value 
95% Confidence Interval for B 
Effect Estimate (B) 
Standard 
Error Lower Bound Upper Bound 
IC Group        -10.366 143.856 -0.072 0.944 -330.898 310.165 
Age (year) 2.118 5.064 0.418 0.685 -9.166 13.401 
Female Sex 58.693 109.761 0.535 0.605 -185.870 303.257 
Diabetes -124.471 162.025 -0.768 0.460 -485.486 236.544 
Systolic BP 
(mmHg) 
-8.591 5.611 -1.531 0.157 -21.093 3.912 
Diastolic BP 
(mmHg) 
11.818 6.018 1.964 0.078 -1.591 25.227 
(Constant) 101.033 573.173 0.176 0.864 -1176.075 1378.142 
Table 9 Multiple regression analysis to evaluate factors that impact ACh dependent endothelial function 
in response to RIPC, measured in PU values. N = 17 
 
 
Dependent Variable: Change in SNP PU  
 
Unstandardized Coefficients 
T Statistic P Value 
95.0% Confidence Interval for B 
Effect Estimate (B) 
Standard 
Error Lower Bound Upper Bound 
IC Group -58.607 96.512 -0.607 0.557 -273.650 156.435 
Age (year) 0.621 3.397 0.183 0.859 -6.949 8.191 
Female Sex -36.872 73.638 -0.501 0.627 -200.948 127.205 
Diabetes -21.391 108.702 -0.197 0.848 -263.594 220.812 
Systolic BP 
(mmHg) 
-3.294 3.765 -0.875 0.402 -11.682 5.095 
Diastolic BP 
(mmHg) 
9.020 4.037 2.234 0.049 0.024 18.016 
(Constant) -268.451 384.538 -0.698 0.501 -1125.256 588.354 
Table 10 Multiple regression analysis to evaluate factors that impact ACh independent (SNP) 




11.3.2 Pulse wave analysis 
 












Spearman’s correlation was performed to assess any association between before and 
after values for pulse wave analysis. Before and after scores were strongly correlated 
(Figure 17, Spearman’s rho = 0.841, p = <0.001). 
 
 
Figure 17 Scatter plot looking at correlation of PWA values before and after RIPC across all study 
participants (n=17) 
 
Looking at differences between IC and HV we see that there is a significant difference 
in pre intervention PWA values (p = 0.015) and also significant differences in post 
intervention values (p <0.001) between IC and HV (Table 11). 
 
Table 11  Comparison of effect of RIPC on arterial stiffness between IC and HV as measured by PWA 
(AIx). Mann-Whitney Tests evaluating differences in the pre-RIPC PWA values between IC and HV 




Statistical test   P value   




11.0 (35.0) Mann-Whitney 
Test 
0.015 
     
Post RIPC PWA (AIx) 
Median (IQR) 
39.5 (12.75) 13.0 (24.5) Mann-Whitney 
Test 
<0.001 
     
Change in PWA (AIx) 
After RIPC 
Median (IQR) 
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groups, post-RIPC PWA values between IC and HV groups, and change in PWA values (post minus 
pre PWA values) between IC and HV groups 
 
 
In order to assess whether being a healthy volunteer or participant with IC was 
predictive of post RIPC pulse wave analysis scores we preformed regression analysis 
controlling for potential confounders (Table 12). 
 
Multiple Regression Analysis PWA 
 





T Statistic P Value 
95% Confidence Interval for B 
Effect 
Estimate (B) Std. Error Lower Bound Upper Bound 
Pre RIPC PWA 0.536 0.239 2.240 0.052 -0.005 1.078 
IC group 14.337 6.339 2.262 0.050 -0.003 28.677 
Age (year) 0.022 0.358 .062 0.952 -0.789 0.833 
Systolic BP 
(mmHg) 
-0.135 0.250 -0.539 0.603 -0.700 0.430 
Diastolic BP 
(mmHg) 
0.295 0.332 0.887 0.398 -0.457 1.046 
diabetes -4.626 7.408 -0.624 0.548 -21.384 12.132 
Female Sex 1.436 4.904 0.293 0.776 -9.657 12.529 
(Constant) -4.531 31.177 -0.145 0.888 -75.060 65.997 
Table 12 Multiple regression analysis to evaluate factors that impact arterial stiffness in response to 
RIPC, as measured by PWA(AIx). N= 17 
 
When controlling for potential confounders being a participant with IC was associated 
with a 14.337 point higher PWA score after undergoing the RIPC protocol when 
compared to healthy volunteers. This was statistically significant, p = 0.05.  
 
 
11.3.3 Pulse Wave Velocity 
 











Spearman’s correlation was performed to assess any association between before and 
after values for pulse wave analysis. Before and after scores were strongly correlated 
(Figure 18).  
 
 
Figure 18 Scatter plot looking at correlation of PWV values before and after RIPC (Spearman’s rho = 
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Mann-Whitney comparing PWV in IC and HV 
 
Healthy volunteers tended to have lower PWV values before and after the intervention 
compared to IC although this was not statistically significant (Table 13).  
 
Table 13 Comparison of effect of RIPC on arterial stiffness between IC and HV as measured by PWV. 
Mann-Whitney tests comparing PWV values, measured in metres per second, in IC and HV 
 
 
HV tended to have lower PWV values post RIPC compared with before RIPC PWV 
values, however this was not statistically significant. Very little difference was 
observed in the PWV scores before and after RIPC for IC (Table 14). 
 
Table 14 Effect of RIPC on arterial stiffness as measured in PWV (m/s). Wilcoxon Signed Rank Test 
comparing before and after PWV values in the whole study group (N = 17) and split separately into IC 










Statistical test   P value   
Pre RIPC PWV (m/s) 
Median (IQR) 
9.5 (2.72) 7.8 (2.60) Mann-Whitney Test 0.139 
     
Post RIPC PWV (m/s) 
Median (IQR) 
8.95 (2.13) 7.2 (2.25) Mann-Whitney Test 0.277 
     
Change in PWV (m/s) After 
RIPC 
Median (IQR) 
-0.60 (2.1) -0.20 (1.65) Mann-Whitney Test 0.815 




Statistical test   P value   
All Patients   
Median (IQR) 
8.8 (2.6) 8.1 (2.5) Wilcoxon Signed 
Rank Test 
0.246 
     
Healthy Volunteers 
Median (IQR) 
7.8 (2.60) 7.2 (2.25) Wilcoxon Signed 
Rank Test 
0.513 
     
Intermittent Claudicants  
Median (IQR) 
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Multiple Regression Analysis PWV 
When included into a multiple regression model there were no statistically significant 
predictors of change in PWV values after RIPC (Table 15).  
 




T Statistic P Value 
95.0% Confidence Interval 
for B 
Effect 
Estimate (B) Std. Error Lower Bound 
Upper 
Bound 
IC group -1.516 2.316 -0.655 0.529 -6.755 3.723 
Pre RIPC PWV 0.841 0.701 1.199 0.261 -0.745 2.427 
Age (year) 0.070 0.098 0.713 0.494 -0.152 0.293 
Female Sex -0.571 1.901 -0.300 0.771 -4.872 3.730 
diabetes 0.785 2.890 0.272 0.792 -5.753 7.323 
Systolic BP 
(mmHg) 
-0.009 0.129 -0.073 0.944 -0.301 0.283 
Diastolic BP 
(mmHg) 
0.125 0.108 1.161 0.275 -0.119 0.369 
(Constant) -10.194 14.710 -0.693 0.506 -43.471 23.084 
Table 15 Multiple regression analysis to evaluate factors that impact arterial stiffness in response to 
RIPC, as measured by PWV(m/s). N= 17 
 
11.3.4 Post Occlusive Reactive Hyperaemia 
 
The peak perfusion units for PORH were calculated by subtracting the biological zero 




There was a significant correlation between peak PU values before and after the RIPC 
protocol (Figure 19). 
 
 




Figure 19: Scatter plot looking at correlation of PORH PU values before and after RIPC (Spearman’s 
rho = 0.665, p = 0.013, n=13) 
 
 
Multiple Regression Analysis PORH 
 
In order to assess whether being a healthy volunteer or participant with IC was 
predictive of post RIPC PORH scores we preformed regression analysis controlling 
for potential confounders (Table 16). None of the variables included in the model were 
significant. 
 
Table 16 Multiple regression analysis to evaluate factors that impact endothelial function as determined 





















PU Before RIPC 0.724 0.775 0.934 0.393 -1.268 2.716 
IC Group 13.324 150.291 0.089 0.933 -373.011 399.659 
age 6.922 6.161 1.124 0.312 -8.915 22.759 
Female Sex 28.186 124.202 0.227 0.829 -291.086 347.458 
Diabetes -77.036 195.645 -0.394 0.710 -579.957 425.885 
Systolic BP -7.130 7.393 -0.964 0.379 -26.135 11.875 
Diastolic BP 0.555 8.347 0.067 0.950 -20.902 22.012 
(Constant) 588.393 1349.947 0.436 0.681 -2881.757 4058.542 
 





The main aim of the study was to assess if repeated bouts of RIPC could improve 
endothelial function. Looking at the multiple regression analysis model for PWA it 
seems that HV have significantly lower arterial stiffness, as measured by AIx@75, 
compared to IC. This would suggest that the RIPC intervention may be having a 
greater effect on healthy volunteers. The most obvious differences between HV and 
IC participants will be level of endothelial dysfunction. Based purely on lack of clinical 
symptoms it could be assumed that the HV participants have superior endothelial 
function compared to IC. It may be that a healthy endothelium is more responsive to 
RIPC. Perhaps patients with IC, and by inference a degree of endothelial dysfunction, 
need more consecutive days of RIPC.  
 
When devising the study protocol we used iontophoresis as a measure of endothelial 
function and tested only healthy volunteers. Despite seeing improvements in 
endothelial function with iontophoresis in HV perhaps we may not have seen such 
improvements if we had trialled the same protocol in IC participants. Our sample size 
was underpowered given the numbers that were recruited to the study. Based on 
previous studies in humans in RIPC(54) and from studies using iontophoresis and 
laser Doppler imaging (primary outcome measure)(71) future studies should aim to 
recruit 75 participants as this will give sufficient power at the 80% level with a 
probability of P<0.05 to detect significant before and after improvements in endothelial 
function. 
 
Again, when devising the study protocol, we did see greater improvements in ACh 
mediated vasodilation in participants who completed seven days of RIPC compared 
to those who completed four days. It is possible that had IC participants, in the current 
study, completed a longer RIPC protocol of seven days we may have observed an 
improvement there also. The PWA results would seem to contradict other research 
looking at changes in arterial stiffness in healthy volunteers and those with CVD(54) 
where RIPC improved arterial stiffness in patients with CVD, who have a similar 
burden of disease to IC, and not in HV. Zagidullin et. al(54) also found with the 
improvement in arterial stiffness there was an improvement in systolic blood pressure 
suggesting an overall improvement in risk factors for CVD. In the current study arterial 
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stiffness was measured in a standardised and validated way which has been shown 
to be a surrogate measure of global endothelial function(64) however caution is 
required in presuming that our observed results are solely related to improvements in 
endothelial function. Arterial stiffness is also partly dependent on vasomotor tone 
which is mostly controlled by smooth muscle cells. This is independent of the 
endothelium but is related to NO(12) passing through the endothelial intima. As RIPC 
has been shown to increase bioavailability of NO this could partly explain the observed 
results. Although all of the other findings were not statistically significant there were 




Healthy volunteers again seem to have a greater improvement in endothelial-
dependent ACh vasodilation compared to IC. This result did not reach statistical 
significance but looking at the data for response to endothelial-independent SNP 
mediated vasodilation there is much less of an improvement after the RIPC 
intervention. This would fit with previous studies that have found RIPC to have a 
targeted effect on the endothelium by increased production of NO(29). Regression 
analysis would seem to support this trend as well as it suggested, whilst controlling for 
confounding variables, that IC participants had reduced response to ACh mediated 
vasodilation compared to HV. Gender seems to be playing a role as being female 
resulted in greater improvements in endothelial function compared to males. A larger 
sample size is required to see if these trends would persist and if it would reach 
statistical significance. 
 
Additionally, in future research, it would be of benefit to account for other variables 
that may be having an effect on results obtained. There is a strong association 
between diabetes and endothelial dysfunction and so measuring glucose levels could 
be of benefit. Studies have shown vasodilatory response to ACh iontophoresis is 
blunted in the presence of high glucose levels whether it be an acute rise or chronic 
disease(55)(72). In the current study we could have recorded patient BMI to examine 
if it had any effect on results. Obesity, as measured by very high BMI, is the excessive 
deposition of fat that can interfere with normal metabolic processes in the body. 
Increased accumulation of macronutrients on the adipose tissues can stimulate 
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Post Occlusive Reactive Hyperaemia 
 
There were no significant changes conferred to before and after PORH values. It 
would seem that RIPC has no effect on PORH. RIPC is posited to effect the 
endothelium locally. The increased vasodilatory response when the occluded artery is 
released is primarily a mechanical stimulus (i.e occlusion of an artery with blood 
pressure cuff) and it is thought that this is partially dependent on myogenic-mediated 
vasodilation. It seems that RIPC has had no statistically significant effect on either. In 
a study looking at PORH in patients who have undergone seven days of RIPC there 
was an improvement in vascular reactivity as measured by PORH but this did not 
reach statistical significance(74). Perhaps as discussed participants should undergo 
seven days of RIPC although it does remain to be seen if this would produce a 




Unfortunately, blood analyses were unable to be carried out due to the onset of the 
coronavirus pandemic. It would have been useful to have these results as it would 
have allowed for analysis of correlations between plasma levels of markers of vascular 
function and changes seen in microvascular and macrovascular assessments. TNF-⍺	
was one of the main cytokines we intended to study. As discussed in the introduction 
TNF-⍺	can be proinflammatory but may also play a role in the SAFE pathway when 
initiated by RIPC, dependent on its binding to the TNF receptor 2. Increased levels of 
IL-1β & IL-6 have been associated with impaired endothelial function and increased 
risk of cardiovascular events(75) IL-10 has a protective effect on endothelial function 
however both IL-6 and IL-10 have a role in some of the protective effects seen in RIPC. 
It is thought that both IL-6 and IL-10 are both activated via STAT3 and have been 
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12.1 LIMITATIONS OF STUDY 
 
The main limitation of the study is the sample size. With 17 participants any data 
gathered would be unlikely to reach statistical significance. In general when splitting 
the sample group into HV and IC the two groups were not well matched in terms of 
age or other risk factors such as smoking. None of the HV were smokers or diabetic. 
For the purposes of the study it was felt that this was an appropriate mismatch. 
Participants with no clinical symptoms of atherosclerotic disease can be assumed to 
have a healthier endothelium than the IC participants. HV participants were younger 
which again suggests healthier endothelium. One of the main aims of the study was 
to assess the effects of RIPC endothelial function and so there is benefit in examining 
its effect on healthy endothelium and diseased endothelium.  
 
The study did not employ a placebo group. Having a placebo group would allow better 
analysis of the RIPC protocol and allow to control for confounding factors that may 
affect study results such as smoking, exercising or taking on food or drink (especially 
caffeine) prior to assessment.  
 
Compliance with the RIPC protocol may have been poor. Carrying out the protocol 
required using a blood pressure cuff at home for four consecutive days. There is a 
possibility that less motivated participants may not have completed the protocol in its 
entirety or may have partially completed it. It was impossible to control for this as the 
resources were not available to have patients attend the lab each day to be observed 
completing the RIPC protocol.  
 
When performing iontophoresis, the skin over the anterior compartment of the lower 
leg was used for analysis. The rationale for this was that as patients with claudication 
are generally affected by atherosclerotic disease in the arteries supplying the lower 
limbs it would be of benefit to measure microvascular response over this area. 
However, the maximal penetration of iontophoresis is about 1-1.5mm(56). The level 
of drug penetration can be affected by differences in skin composition between 
participants. The dermal layer in the leg tends to be deeper than in the arm. With RIPC 
the potential improvements should be conferred to remote sites. If these 
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improvements are observed in the microvascular bed of the arm then it could be 
inferred that there is a similar improvement in the lower leg arteries.  
 
When analysing PORH there were data for 13 participants. In two cases this was due 
to machine software failure and in the other two the participants were unable to tolerate 
5 minutes of cuff occlusion. A complete case analysis was performed, and as a result, 
patients with any missing data were excluded. This is an acceptable approach when 
there are no systematic differences between patients with complete and incomplete 
data.  
 
12.2 SUGGESTIONS FOR FUTURE RESEARCH 
 
Future research should focus on ensuring adequate sample size so that the study is 
powered appropriately. In terms of recruiting participants and compliance with the 
protocol perhaps with the current increased use of Microsoft Teams and Zoom 
meetings it may be of benefit for participants to have an online conference 
appointment with researchers to ensure that they are managing with the RIPC 
protocol. This would certainly be convenient for the participants but obviously would 
be more time consuming for researchers. It would, however, ensure that the protocol 
is being followed as intended.  
 
As there is still uncertainty as to what length of RIPC protocol is of greatest benefit 
when examining differences in endothelial function in IC and HV. Will better results be 
obtained in those who undergo seven days of RIPC as opposed to four days. A paper 
published after the current study concluded has shown that seven consecutive days 
of RIPC does produce a statistically significant difference in SNP mediated 
vasodilation, via iontophoresis, compared to baseline(77). The same study however 
did not find any difference between a seven-day RIPC protocol and a fourteen-day 
protocol suggesting there may be a saturation point to repeated bouts of RIPC.  
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14 APPENDIX 1 
 


















Pt ID Group sex age smoking diabetes Systolic BP Diastolic BP 
1 HV Female 57.00 Non Non 130.00 80.00 
2 IC Male 57.00 Smoker Non 135.00 88.00 
3 HV Male 40.00 Non Non 124.00 88.00 
4 IC Female 56.00 Smoker Non 135.00 78.00 
5 IC Male 81.00 Smoker Non 124.00 64.00 
6 HV Male 64.00 Non Non 140.00 66.00 
7 HV Male 40.00 Non Non 112.00 82.00 
8 IC Male 60.00 Smoker Diabetic 117.00 64.00 
9 IC Male 62.00 Smoker Diabetic  124.00 81.00 
10 HV Female 64.00 Non Non 150.00 74.00 
11 IC Male 60.00 Smoker Non 155.00 95.00 
12 IC Male 75.00 Smoker Non 132.00 85.00 
13 IC Male 58.00 Smoker Non 126.00 82.00 
14 HV Female 30.00 Non Non 117.00 82.00 
15 HV Female 30.00 Non Non 125.00 82.00 
16 HV Male 30.00 Non Non 119.00 71.00 
17 HV Male 30.00 Non Non 108.00 61.00 
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Pt ID Group PWV.pre PWV.post PWV.diff PWA.pre PWA.post PWA.diff 
1 HV 6.40 5.90 -0.50 38.00 28.00 -10.00 
2 IC 9.70 8.70 -1.00 34.00 49.00 15.00 
3 HV 8.90 9.40 0.50 38.00 32.00 -6.00 
4 IC 7.10 5.80 -1.30 37.00 41.00 4.00 
5 IC 13.30 9.20 -4.10 43.00 38.00 -5.00 
6 HV 7.80 8.10 0.30 30.00 12.00 -18.00 
7 HV 10.90 8.80 -2.10 11.00 13.00 2.00 
8 IC 8.20 8.00 -0.20 24.00 20.00 -4.00 
9 IC 10.10 10.00 -0.10 35.00 35.00 0.00 
10 HV 6.10 6.90 0.80 35.00 21.00 -14.00 
11 IC 8.80 9.60 0.80 45.00 35.00 -10.00 
12 IC 11.40 19.50 8.10 79.00 50.00 -29.00 
13 IC 9.30 7.70 -1.60 45.00 44.00 -1.00 
14 HV 10.10 10.40 0.30 -7.00 -10.00 -3.00 
15 HV 7.60 7.10 -0.50 10.00 13.00 3.00 
16 HV 7.40 7.20 -0.20 2.00 -1.00 -3.00 
17 HV 8.80 6.80 -2.00 1.00 1.00 0.00 
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Iontophoresis – SNP 
 
 
Pt ID Group ach.b.base ach.b.peak ach.diff.b ach.a.base ach.a.peak ach.diff.a 
Difference 
PU ACH 
1 HV 32.00 278.00 246.00 59.00 420.00 361.00 115.00 
2 IC 131.00 423.00 292.00 69.00 138.00 69.00 -223.00 
3 HV 26.00 63.00 37.00 91.00 451.00 360.00 323.00 
4 IC 52.00 337.00 285.00 21.00 594.00 573.00 288.00 
5 IC 16.00 257.00 241.00 22.00 55.00 33.00 -208.00 
6 HV 39.00 289.00 250.00 44.00 264.00 220.00 -30.00 
7 HV 25.00 157.00 132.00 6.00 237.00 231.00 99.00 
8 IC 26.00 216.00 190.00 50.00 82.00 32.00 -158.00 
9 IC 35.00 80.00 45.00 9.00 46.00 37.00 -8.00 
10 HV 24.00 398.00 374.00 95.00 183.00 88.00 -286.00 
11 IC 23.00 34.00 11.00 33.00 53.00 20.00 9.00 
12 IC 78.00 127.00 49.00 32.00 403.00 371.00 322.00 
13 IC 13.00 306.00 293.00 28.00 437.00 409.00 116.00 
14 HV 26.00 299.00 273.00 39.00 501.00 462.00 189.00 
15 HV 0.00 215.00 215.00 9.00 244.00 235.00 20.00 
16 HV 33.00 193.00 160.00 21.00 188.00 167.00 7.00 
17 HV 27.00 164.00 137.00 11.00 113.00 102.00 -35.00 
Pt 
ID Group snp.b.base snp.b.peak snp.diff.b snp.a.base snp.a.peak snp.diff.a 
Difference 
Flux SNP 
1 HV 29.00 423.00 394.00 55.00 413.00 358.00 -36.00 
2 IC 248.00 256.00 8.00 75.00 219.00 144.00 136.00 
3 HV 32.00 63.00 31.00 38.00 188.00 150.00 119.00 
4 IC 49.00 386.00 337.00 44.00 192.00 148.00 -189.00 
5 IC 23.00 211.00 188.00 17.00 110.00 93.00 -95.00 
6 HV 28.00 168.00 140.00 49.00 253.00 204.00 64.00 
7 HV 34.00 223.00 189.00 3.00 196.00 193.00 4.00 
8 IC 24.00 154.00 130.00 51.00 73.00 22.00 -108.00 
9 IC 66.00 89.00 23.00 40.00 64.00 24.00 1.00 
10 HV 58.00 258.00 200.00 54.00 99.00 45.00 -155.00 
11 IC 32.00 76.00 44.00 20.00 87.00 67.00 23.00 
12 IC 60.00 314.00 254.00 165.00 438.00 273.00 19.00 
13 IC 11.00 34.00 23.00 1.00 151.00 150.00 127.00 
14 HV 4.00 53.00 49.00 33.00 395.00 362.00 313.00 
15 HV 0.00 78.00 78.00 6.00 121.00 115.00 37.00 
16 HV 0.00 151.00 151.00 0.00 80.00 80.00 -71.00 
17 HV 15.00 132.00 117.00 7.00 7.00 0.00 -117.00 
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Pt ID Group BioZeroBefore PeakPUBefore 
True PU 
Before 
RIPC BioZeroAfter PeakPUAfter 
True PU 
After RIPC 
1 HV 30.00 204.10 174.10 47.50 374.20 326.70 
2 IC 24.80 103.60 78.80 25.60 110.20 84.60 
3 HV 30.00 184.40 154.40 35.90 148.60 112.70 
4 IC 32.80 120.00 87.20 29.60 124.30 94.70 
5 IC       
6 HV 34.70 130.00 95.30 19.70 190.00 170.30 
7 HV       
8 IC 20.00 309.60 289.60 30.00 361.00 331.00 
9 IC 42.80 105.00 62.20 30.00 209.80 179.80 
10 HV       
11 IC 30.10 109.40 79.30 40.00 86.20 46.20 
12 IC 51.20 185.00 133.80 48.50 196.00 147.50 
13 IC 29.00 238.70 209.70 23.80 600.00 576.20 
14 HV 54.70 260.00 205.30 46.10 225.40 179.30 
15 HV 29.90 190.00 160.10 25.80 120.00 94.20 
16 HV 99.00 548.40 449.40 102.20 345.60 243.40 
17 HV       
